Saturday 17 October 2026
Export STOK’s income statement to Excel — free account
Stoke Therapeutics, Inc.
STOK Healthcare Biotechnology
Stoke Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $184.4 million, up 404.5% from fiscal 2024. In the quarter to June 2026, revenue fell 32.5%, EPS fell 132.5% and free cash flow fell 129.0%, each against the same quarter a year earlier.
24.17
0.44
−1.79%
Follow STOK
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
7 | 5 | 3 | 3 |
| 15.02% | (2.37%) | (45.58%) | (61.10%) | ||
| 12.41% | (2.00%) | (39.94%) | (53.41%) | ||
ROIC |
28.42% | (18.98%) | (225.55%) | (264.77%) | |
Return on Tangible Assets |
17.35% | (2.74%) | (51.56%) | (72.84%) | |
Average Days of Receivables |
19.24 | 15.65 | 69.87 | 115.36 | |
Free Cash Flow per Share |
0.89 | 0.76 | (2.34) | (2.74) | |
Free Cash Flow |
52.37 | 44.92 | (147.69) | (180.68) | |
Capital Expenditures |
(0.48) | (0.67) | (0.87) | (2.69) | |
| Other line items | |||||
Cash ROIC |
9.41% | 7.05% | (20.00%) | (28.30%) | |
Accounts Receivable Turnover |
35.68 | 35.90 | 9.51 | 5.34 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
58.19% | 74.79% | 451.74% | 611.01% | |
Selling, General and Administrative Expense of Revenue |
28.59% | 36.38% | 225.71% | 298.68% | |
Share Based Compensation of Revenue |
14.36% | 17.48% | 106.73% | 135.72% | |
Operating CF/Net income |
1.30 | (6.62) | 0.86 | 0.86 | |
Depreciation/Fixed assets |
0.17 | 0.20 | 0.21 | (0.03) | |
Capex/Depreciation |
(0.91) | (1.05) | (1.20) | 17.26 | |
Revenue per Share |
3.51 | 3.11 | 0.51 | 0.42 | |
Operating CF per Share |
0.90 | 0.77 | (2.33) | (2.70) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.04) | |
Capex to Sales |
0.00 | 0.00 | 0.03 | 0.10 |
Columns are period end dates